Feedback / Questions
SPG302 - Spinogenix
https://www.prnewswire.com/news-releases/spinogenix-announces-full-enrollment-in-its-phase-2-trial-evaluating-spg302-as-a-first-in-class-synaptic-regenerative-therapy-for-alzheimers-disease-302489503.html
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next